Home » Newsletters » BioWorld Science

BioWorld Science

June 29, 2022

View Archived Issues

CYSLTR1 blockade as a strategy to prevent breast cancer progression

Researchers identify DAW1 gene variants linked to motile ciliopathy

Design of a novel TAM inhibitor as a potential cancer therapy

Orion Corporation patents new CYP11A1 inhibitors

Wellstat Therapeutics divulges novel uridine derivatives

Eternity Bioscience synthesizes IRAK4 inhibitors

Vilnius University presents new carbonic anhydrase IX ligands

KalVista Pharmaceuticals patents FXIIa inhibitors

[68Ga]NOTA-cc90 demonstrates imaging of LAG-3 expression on tumor-infiltrating lymphocytes

FABP5 inhibitor ART26.12 shows promise for chemotherapy-induced pain

Ono and Fate Therapeutics expand drug discovery collaboration to include CAR-NK cell therapy

FDA clears IND for MALT1 inhibitor SGR-1505 for B-cell lymphomas

BiomX collaborates with Boehringer Ingelheim on biomarkers for IBD-associated pathogenic bacterium

Palleon and Henlius collaborate to codevelop bifunctional sialidase therapeutics

Series B financing at MiroBio funds development of checkpoint agonists to treat autoimmune diseases

miR-135b discriminates tongue cancer from noncancerous tissue

PDX models of radiation-resistant pediatric high-grade glioma show sensitivity to MAPK inhibition

Scorpion selects Exon 20 mutant EGFR inhibitor STX-721 as development candidate

Myelin-forming cells change in multiple brain diseases

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...